Oral Low-Dose Naltrexone in the Treatment of Frontal Fibrosing Alopecia and Lichen Planopilaris: An Uncontrolled Open-Label Prospective Study

Background Frontal fibrosing alopecia (FFA) and lichen planopilaris (LPP) is scarring alopecias with limited evidence supporting their treatment options. We investigated the use of low-dose naltrexone (3 mg oral daily) as adjunctive therapy in the treatment of FFA and LPP. Methods A single-center, u...

Full description

Saved in:
Bibliographic Details
Published in:Curēus (Palo Alto, CA) CA), 2023-01, Vol.15 (1), p.e34169-e34169
Main Authors: Hamel, Remi K, Chen, Ling, O'Connell, Cailin, Mann, Caroline
Format: Article
Language:English
Subjects:
Alopecia
Baldness
Demographics
Dermatology
Erythema
Hair loss
Narcotics
Pain
Patient assessment
Pruritus
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites cdi_FETCH-LOGICAL-c299t-175a691e3a279abbc4ff2db2acca9c0e27fff35bea5b621194db8580a27b77b43
container_end_page e34169
container_issue 1
container_start_page e34169
container_title Curēus (Palo Alto, CA)
container_volume 15
creator Hamel, Remi K
Chen, Ling
O'Connell, Cailin
Mann, Caroline
description Background Frontal fibrosing alopecia (FFA) and lichen planopilaris (LPP) is scarring alopecias with limited evidence supporting their treatment options. We investigated the use of low-dose naltrexone (3 mg oral daily) as adjunctive therapy in the treatment of FFA and LPP. Methods A single-center, uncontrolled open-label prospective study was performed, with 26 patients who took low-dose naltrexone for one year included in the per-protocol analysis. Both patient-reported (pruritus and burning/pain) and physician-assessed (erythema, scale, and scalp involvement) outcomes were analyzed. Results There were decreases in erythema and scale for the overall longitudinal outcomes using linear mixed effects model analysis. However, only erythema had a significant decrease at 12 months compared with baseline. Mean erythema decreased by 0.93 at 12 months compared with baseline on a 0-3-point scale (p
doi_str_mv 10.7759/cureus.34169
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9950001</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2780483114</sourcerecordid><originalsourceid>FETCH-LOGICAL-c299t-175a691e3a279abbc4ff2db2acca9c0e27fff35bea5b621194db8580a27b77b43</originalsourceid><addsrcrecordid>eNpdkU9PHSEUxUlTU41113VD0k0XHQvMH4YumrxYX9tk4jOprgkwd3wYHkxhxtYP4Xcuz2eNuoKE3z3ccw5C7yg55rwWn80cYU7HZUUb8QodMNq0RUvb6vWT-z46SumaEEIJZ4STN2i_bNqq5JQdoLtVVA534U_xLSTAZ8pNEf4GD9h6PK0BX0RQ0wb8hMOAlzH4KfNLq2NI1l_hhQsjGKuw8j3urFmDx-dO-TBap6JNX_DC40tv8lwMzkGPVyP4olMaHD7PInl6sjeAf01zf_sW7Q3KJTh6OA_R5fL04uRH0a2-_zxZdIVhQkwF5bVqBIVSMS6U1qYaBtZrpoxRwhBgfBiGstagat0wSkXV67ZuScY157oqD9HXne446w30JtvLMcgx2o2KtzIoK5-_eLuWV-FGClFvg8wCHx8EYvg9Q5rkxiYDLjuHMCfJeEuqtqR0-9eHF-h1mKPP9u6pJguyJlOfdpTJmaQIw-MylMht1XJXtbyvOuPvnxp4hP8XW_4D-deopQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2780650026</pqid></control><display><type>article</type><title>Oral Low-Dose Naltrexone in the Treatment of Frontal Fibrosing Alopecia and Lichen Planopilaris: An Uncontrolled Open-Label Prospective Study</title><source>Open Access: PubMed Central</source><source>Publicly Available Content Database (Proquest) (PQ_SDU_P3)</source><source>Coronavirus Research Database</source><creator>Hamel, Remi K ; Chen, Ling ; O'Connell, Cailin ; Mann, Caroline</creator><creatorcontrib>Hamel, Remi K ; Chen, Ling ; O'Connell, Cailin ; Mann, Caroline</creatorcontrib><description>Background Frontal fibrosing alopecia (FFA) and lichen planopilaris (LPP) is scarring alopecias with limited evidence supporting their treatment options. We investigated the use of low-dose naltrexone (3 mg oral daily) as adjunctive therapy in the treatment of FFA and LPP. Methods A single-center, uncontrolled open-label prospective study was performed, with 26 patients who took low-dose naltrexone for one year included in the per-protocol analysis. Both patient-reported (pruritus and burning/pain) and physician-assessed (erythema, scale, and scalp involvement) outcomes were analyzed. Results There were decreases in erythema and scale for the overall longitudinal outcomes using linear mixed effects model analysis. However, only erythema had a significant decrease at 12 months compared with baseline. Mean erythema decreased by 0.93 at 12 months compared with baseline on a 0-3-point scale (p&lt;0.0001, 95% mean CI [-1.32, -0.53]). There was no statistically significant difference comparing 12 months to baseline for the other outcomes including pruritus, burning/pain, and scalp involvement. Limitations include the possibility of spontaneous stabilization, concurrent medications, a small sample size with limited racial diversity, and mild subjective symptoms at baseline. Conclusion Our study supports further investigation of oral low-dose naltrexone as adjunctive therapy in the treatment of FFA and LPP if there is prominent erythema, and possibly scale.</description><identifier>ISSN: 2168-8184</identifier><identifier>EISSN: 2168-8184</identifier><identifier>DOI: 10.7759/cureus.34169</identifier><identifier>PMID: 36843712</identifier><language>eng</language><publisher>United States: Cureus Inc</publisher><subject>Alopecia ; Baldness ; Demographics ; Dermatology ; Erythema ; Hair loss ; Narcotics ; Pain ; Patient assessment ; Pruritus</subject><ispartof>Curēus (Palo Alto, CA), 2023-01, Vol.15 (1), p.e34169-e34169</ispartof><rights>Copyright © 2023, Hamel et al.</rights><rights>Copyright © 2023, Hamel et al. This work is published under https://creativecommons.org/licenses/by/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>Copyright © 2023, Hamel et al. 2023 Hamel et al.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c299t-175a691e3a279abbc4ff2db2acca9c0e27fff35bea5b621194db8580a27b77b43</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2780650026/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2780650026?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,37013,38516,43895,44590,53791,53793,74412,75126</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36843712$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hamel, Remi K</creatorcontrib><creatorcontrib>Chen, Ling</creatorcontrib><creatorcontrib>O'Connell, Cailin</creatorcontrib><creatorcontrib>Mann, Caroline</creatorcontrib><title>Oral Low-Dose Naltrexone in the Treatment of Frontal Fibrosing Alopecia and Lichen Planopilaris: An Uncontrolled Open-Label Prospective Study</title><title>Curēus (Palo Alto, CA)</title><addtitle>Cureus</addtitle><description>Background Frontal fibrosing alopecia (FFA) and lichen planopilaris (LPP) is scarring alopecias with limited evidence supporting their treatment options. We investigated the use of low-dose naltrexone (3 mg oral daily) as adjunctive therapy in the treatment of FFA and LPP. Methods A single-center, uncontrolled open-label prospective study was performed, with 26 patients who took low-dose naltrexone for one year included in the per-protocol analysis. Both patient-reported (pruritus and burning/pain) and physician-assessed (erythema, scale, and scalp involvement) outcomes were analyzed. Results There were decreases in erythema and scale for the overall longitudinal outcomes using linear mixed effects model analysis. However, only erythema had a significant decrease at 12 months compared with baseline. Mean erythema decreased by 0.93 at 12 months compared with baseline on a 0-3-point scale (p&lt;0.0001, 95% mean CI [-1.32, -0.53]). There was no statistically significant difference comparing 12 months to baseline for the other outcomes including pruritus, burning/pain, and scalp involvement. Limitations include the possibility of spontaneous stabilization, concurrent medications, a small sample size with limited racial diversity, and mild subjective symptoms at baseline. Conclusion Our study supports further investigation of oral low-dose naltrexone as adjunctive therapy in the treatment of FFA and LPP if there is prominent erythema, and possibly scale.</description><subject>Alopecia</subject><subject>Baldness</subject><subject>Demographics</subject><subject>Dermatology</subject><subject>Erythema</subject><subject>Hair loss</subject><subject>Narcotics</subject><subject>Pain</subject><subject>Patient assessment</subject><subject>Pruritus</subject><issn>2168-8184</issn><issn>2168-8184</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>COVID</sourceid><sourceid>PIMPY</sourceid><recordid>eNpdkU9PHSEUxUlTU41113VD0k0XHQvMH4YumrxYX9tk4jOprgkwd3wYHkxhxtYP4Xcuz2eNuoKE3z3ccw5C7yg55rwWn80cYU7HZUUb8QodMNq0RUvb6vWT-z46SumaEEIJZ4STN2i_bNqq5JQdoLtVVA534U_xLSTAZ8pNEf4GD9h6PK0BX0RQ0wb8hMOAlzH4KfNLq2NI1l_hhQsjGKuw8j3urFmDx-dO-TBap6JNX_DC40tv8lwMzkGPVyP4olMaHD7PInl6sjeAf01zf_sW7Q3KJTh6OA_R5fL04uRH0a2-_zxZdIVhQkwF5bVqBIVSMS6U1qYaBtZrpoxRwhBgfBiGstagat0wSkXV67ZuScY157oqD9HXne446w30JtvLMcgx2o2KtzIoK5-_eLuWV-FGClFvg8wCHx8EYvg9Q5rkxiYDLjuHMCfJeEuqtqR0-9eHF-h1mKPP9u6pJguyJlOfdpTJmaQIw-MylMht1XJXtbyvOuPvnxp4hP8XW_4D-deopQ</recordid><startdate>20230124</startdate><enddate>20230124</enddate><creator>Hamel, Remi K</creator><creator>Chen, Ling</creator><creator>O'Connell, Cailin</creator><creator>Mann, Caroline</creator><general>Cureus Inc</general><general>Cureus</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>COVID</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20230124</creationdate><title>Oral Low-Dose Naltrexone in the Treatment of Frontal Fibrosing Alopecia and Lichen Planopilaris: An Uncontrolled Open-Label Prospective Study</title><author>Hamel, Remi K ; Chen, Ling ; O'Connell, Cailin ; Mann, Caroline</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c299t-175a691e3a279abbc4ff2db2acca9c0e27fff35bea5b621194db8580a27b77b43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Alopecia</topic><topic>Baldness</topic><topic>Demographics</topic><topic>Dermatology</topic><topic>Erythema</topic><topic>Hair loss</topic><topic>Narcotics</topic><topic>Pain</topic><topic>Patient assessment</topic><topic>Pruritus</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hamel, Remi K</creatorcontrib><creatorcontrib>Chen, Ling</creatorcontrib><creatorcontrib>O'Connell, Cailin</creatorcontrib><creatorcontrib>Mann, Caroline</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Coronavirus Research Database</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Publicly Available Content Database (Proquest) (PQ_SDU_P3)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Curēus (Palo Alto, CA)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hamel, Remi K</au><au>Chen, Ling</au><au>O'Connell, Cailin</au><au>Mann, Caroline</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Oral Low-Dose Naltrexone in the Treatment of Frontal Fibrosing Alopecia and Lichen Planopilaris: An Uncontrolled Open-Label Prospective Study</atitle><jtitle>Curēus (Palo Alto, CA)</jtitle><addtitle>Cureus</addtitle><date>2023-01-24</date><risdate>2023</risdate><volume>15</volume><issue>1</issue><spage>e34169</spage><epage>e34169</epage><pages>e34169-e34169</pages><issn>2168-8184</issn><eissn>2168-8184</eissn><abstract>Background Frontal fibrosing alopecia (FFA) and lichen planopilaris (LPP) is scarring alopecias with limited evidence supporting their treatment options. We investigated the use of low-dose naltrexone (3 mg oral daily) as adjunctive therapy in the treatment of FFA and LPP. Methods A single-center, uncontrolled open-label prospective study was performed, with 26 patients who took low-dose naltrexone for one year included in the per-protocol analysis. Both patient-reported (pruritus and burning/pain) and physician-assessed (erythema, scale, and scalp involvement) outcomes were analyzed. Results There were decreases in erythema and scale for the overall longitudinal outcomes using linear mixed effects model analysis. However, only erythema had a significant decrease at 12 months compared with baseline. Mean erythema decreased by 0.93 at 12 months compared with baseline on a 0-3-point scale (p&lt;0.0001, 95% mean CI [-1.32, -0.53]). There was no statistically significant difference comparing 12 months to baseline for the other outcomes including pruritus, burning/pain, and scalp involvement. Limitations include the possibility of spontaneous stabilization, concurrent medications, a small sample size with limited racial diversity, and mild subjective symptoms at baseline. Conclusion Our study supports further investigation of oral low-dose naltrexone as adjunctive therapy in the treatment of FFA and LPP if there is prominent erythema, and possibly scale.</abstract><cop>United States</cop><pub>Cureus Inc</pub><pmid>36843712</pmid><doi>10.7759/cureus.34169</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2168-8184
ispartof Curēus (Palo Alto, CA), 2023-01, Vol.15 (1), p.e34169-e34169
issn 2168-8184
2168-8184
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9950001
source Open Access: PubMed Central; Publicly Available Content Database (Proquest) (PQ_SDU_P3); Coronavirus Research Database
subjects Alopecia
Baldness
Demographics
Dermatology
Erythema
Hair loss
Narcotics
Pain
Patient assessment
Pruritus
title Oral Low-Dose Naltrexone in the Treatment of Frontal Fibrosing Alopecia and Lichen Planopilaris: An Uncontrolled Open-Label Prospective Study
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T16%3A34%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Oral%20Low-Dose%20Naltrexone%20in%20the%20Treatment%20of%20Frontal%20Fibrosing%20Alopecia%20and%20Lichen%20Planopilaris:%20An%20Uncontrolled%20Open-Label%20Prospective%20Study&rft.jtitle=Cur%C4%93us%20(Palo%20Alto,%20CA)&rft.au=Hamel,%20Remi%20K&rft.date=2023-01-24&rft.volume=15&rft.issue=1&rft.spage=e34169&rft.epage=e34169&rft.pages=e34169-e34169&rft.issn=2168-8184&rft.eissn=2168-8184&rft_id=info:doi/10.7759/cureus.34169&rft_dat=%3Cproquest_pubme%3E2780483114%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c299t-175a691e3a279abbc4ff2db2acca9c0e27fff35bea5b621194db8580a27b77b43%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2780650026&rft_id=info:pmid/36843712&rfr_iscdi=true